AVC-203-01 is a Phase I, first-in-human trial investigating a CD19/CD20 dual-targeted cell therapy (AVC-203) in patients with relapsed or refractory lymphoma (B-cell malignancies). The primary objective is the evaluation of safety and the determination of the maximum tolerated dose (MTD). The study enrolls adult patients with lymphomas (e.g., DLBCL) who present with relapsed or refractory disease after receiving standard prior treatments. Treatment is administered according to a dose-escalation design. Key secondary endpoints include the assessment of pharmacokinetics (PK), pharmacodynamics (PD), and initial evidence of AVC-203's clinical activity.
This early-stage clinical trial (Phase I) investigates a novel cell therapy called AVC-203, which is specifically designed to recognize two different proteins on cancer cells (CD19 and CD20) simultaneously. The main goal is to test the safety and tolerability of this therapy in adult patients with advanced cancers of the lymphatic system (lymphomas). The study includes adult patients whose disease has returned or has not responded sufficiently to prior treatments. The trial aims to determine the highest safe dose and to understand how the treatment behaves in the body. AVC-203 is a potential new option for patients with relapsed or refractory lymphoma.
